Menu
Not yet recruiting NCT07738874

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care

No phase Interventional Retinopathy of Prematurity (ROP)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ultra-widefield Optical Coherence Tomography (UWF-OCT), Wide-field ophthalmic imaging system.
Who it may be relevant to
Registry conditions: Retinopathy of Prematurity (ROP). Basic parameters: 0 Days — 9 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care 3 (BabySTEPS3)

Overview

Retinopathy of prematurity (ROP) is a disorder of development of the retina and its vasculature that can impact vision in vulnerable preterm neonates for a lifetime. A major barrier to improving ROP outcomes is the lack of easy access and low stress means to obtain objective measures of ROP disease severity across the retina in these infants. The long-term goal of this program is to provide information which will improve preterm infant health and vision via objective bedside imaging and analysis that characterizes retina-wide ROP level of disease, its response to treatment and development, and to rapidly translate this for better early intervention and improved future vision care.

Detailed description

Retinopathy of prematurity (ROP) remains the leading cause of childhood blindness in the US and other developed countries, blinding 150,000-200,000 children worldwide annually and leaving many more visually impaired. This vision loss is lifelong and impacts neurodevelopment. While current treatments including the addition of anti-VEGF therapies decrease the likelihood of severe vision loss from ROP, these benefits have come with a burden of monitoring for recurrence, added to the widespread task of monitoring for onset of treatment requiring ROP. This is a global issue, as the improved survival of younger preterm infants increases the burden of care in a world where there is a worsening shortage of experts for bedside ROP exams.

A major barrier to improving ROP management and outcomes is the lack of easy access to incisive, objective measures of ROP disease severity, especially at critical junctures for referral or treatment, response to treatment and reactivation without causing infant stress in the nursery. ROP monitoring by standard care exam and handheld widefield photographs (e.g., RetCam by Natus) use white light, are stressful to the infant, and are repeated more often in more premature infants and with more severe ROP; their induced stress can contribute to poorer neurodevelopment. Drawing/scores of an exam are subjective, and Retcam photos are limited by loss of view from areas of shadow, worse in eyes with dark pigmentation or vitreous haze, and from avoidance response in infants, especially after term age when ROP retreatment decisions must be made. These may contribute to expert disagreement on ROP disease severity based on such photos. AI-generated models are often based on curated sets of good quality images which do not reflect real-world, lower-quality photos.

With the newest generation of handheld OCTs, a field-of-view wider than ROP photographs is possible, as the researchers have established for the proposed renewal. In the current grant period, they have established that with high speed swept-source OCT imaging of a smaller field-of-view, they can obtain: OCT images of good contrast that are agnostic to fundus pigmentation, less infant stress due to lack of visible light, vascular views further into the margin of the imaging field due to coherence gating inherent to OCT, and reproducible depth-resolved retinal measures of risk (e.g. choroid) for treatment requiring disease and of neovascularization, regression and traction at the vascular-avascular junction. Multiple research groups have studied OCT imaging in preterm infants, but rigorous studies to classify ROP on OCT relative to standard care classification are rare. Without such translation, there is a risk that with the use of OCT images physicians will overtreat features, rather than treating ROP at severity levels based on clinical trial evidence. The proposed study will provide clinician-scientists with more objective and precise OCT-based measures of level of severity within (and relative to) current ROP classification.

Having completed the necessary groundwork, the investigators are prepared to test our hypotheses and validate OCT-based measures for referral warranted (RW) and treatment requiring (TR)-ROP. The researchers will demonstrate through measures of infant stress, scalable grading and AI tools, the basis for OCT imaging use to improve ROP care.

Interventions

  • Device Ultra-widefield Optical Coherence Tomography (UWF-OCT)
    Handheld retinal OCT imaging at the bedside or in clinic with an ultra-widefield handheld optical coherence tomography
  • Device Wide-field ophthalmic imaging system
    Handheld wide-field ophthalmic fundus imaging at the bedside or in clinic

Primary outcome measures

  • Sensitivity and specificity of ultra-widefield OCT vs bionocular indirect ophthalmoscopy or fundus photograph to identify referral-warranted retinopathy of prematurity [Time frame: Up to 60 weeks post-menstrual age]
  • Measurement of infant stress [Time frame: Up to 60 weeks post-menstrual age]
Secondary outcome measures (6)
  • Retinal thickness at the fovea and surrounding optic nerve as measured by OCT reading [Time frame: Up to 9 months corrected age]
  • Artificial Intelligence algorithms to classify ROP [Time frame: Up to 60 weeks post-menstrual age]
  • ROP vascular severity score [Time frame: Up to 9 months corrected age]
  • ROP severity as determined by clinical exam [Time frame: Up to 9 months corrected age]
  • ROP severity as determined by retinal photo reading [Time frame: Up to 9 months corrected age]
  • ROP severity as determined by OCT reading [Time frame: Up to 9 months corrected age]

Eligibility criteria

Inclusion criteria

  • Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
  • Parent/Legal Guardian is able and willing to consent to study participation for the infant
  • Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age < 35 weeks postmenstrual age at first visit
  • Infants transferred to nursery for ROP treatment (some participants)

Exclusion criteria

  • Participant or Parent/Legal Guardian unwilling or unable to provide consent
  • Adult participant or infant/child has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
  • Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Single group
Masking
Double blind
Primary purpose
Other

Study locations

United States · 2 centers
  • Duke University Eye Center — Durham
  • University of Pennsylvania, Center for Preventive Ophthalmology and Biostatistics — Philadelphia

Identifiers

NCT: NCT07738874 · Pro00120254 · R01EY025009

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗